Navitas Life Sciences

Optimized Safety and Efficacy Clinical Trials for a Combination Therapy on Moderate COVID-19 Patients

Our client, a multinational mid-sized pharma company headquartered in India needed an end-to-end clinical trial partner to evaluate a randomized, open label, 8-treatment arm clinical trial to evaluate the safety and efficacy of four marketed drugs in the acute treatment of COVID-19 patients.

Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate COVID-19 patients. From being awarded the studies to date we have:

  • Quickly activated sites within 20 days
  • Achieved FPI within 28 days of study award
  • Accomplished 100% on-time completion of key milestones
  • Comprehensive trial oversight through our in-house analytics platform

Please complete the form to download our case study.

Please complete form to download PDF
First Name
Last Name
Business Email
Job Title
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2020 Navitas Life Sciences | Privacy Policy